$109 Million is the total value of BML Capital Management, LLC's 26 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 35.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SGOV | Buy | ISHARES TR0-3 mnth treasry | $27,180,900 | +50.1% | 270,000 | +50.0% | 24.96% | +53.2% |
| BIL | SPDR SER TRbloomberg 1-3 mo | $18,364,000 | 0.0% | 200,000 | 0.0% | 16.86% | +2.1% | |
| AVIR | Buy | ATEA PHARMACEUTICALS INC | $14,400,000 | +72.2% | 4,800,000 | +114.6% | 13.22% | +75.8% |
| CYT | Buy | CYTEIR THERAPEUTICS INC | $9,230,023 | +9.2% | 3,250,008 | +0.0% | 8.48% | +11.5% |
| AVRO | Buy | AVROBIO INC | $6,162,506 | +2430.9% | 4,001,627 | +1461.4% | 5.66% | +2484.0% |
| ADVM | Sell | ADVERUM BIOTECHNOLOGIES INC | $5,872,500 | -28.4% | 3,915,000 | -24.1% | 5.39% | -26.9% |
| TALS | TALARIS THERAPEUTICS INC | $5,620,000 | -7.6% | 2,000,000 | 0.0% | 5.16% | -5.6% | |
| Buy | ELIEM THERAPEUTICS INC | $5,097,632 | +15.0% | 1,938,263 | +22.4% | 4.68% | +17.4% | |
| ATHA | Sell | ATHIRA PHARMA INC | $3,442,811 | -37.4% | 1,704,362 | -8.6% | 3.16% | -36.1% |
| ASTROTECH CORP | $2,226,141 | -28.7% | 220,410 | 0.0% | 2.04% | -27.2% | ||
| ORMP | Sell | ORAMED PHARMACEUTICALS INC | $2,039,172 | -33.0% | 781,292 | -8.1% | 1.87% | -31.6% |
| ABIO | ARCA BIOPHARMA INC | $1,420,929 | -1.0% | 706,930 | 0.0% | 1.30% | +1.1% | |
| PASG | PASSAGE BIO INC | $1,354,669 | -30.1% | 2,058,767 | 0.0% | 1.24% | -28.6% | |
| FBRX | Buy | FORTE BIOSCIENCES INC | $1,166,247 | -35.4% | 1,761,702 | +1.5% | 1.07% | -34.0% |
| MIST | MILESTONE PHARMACEUTICALS IN | $844,750 | +8.8% | 272,500 | 0.0% | 0.78% | +11.0% | |
| Sell | ENLIVEN THERAPEUTICS INC | $683,000 | -54.9% | 50,000 | -32.6% | 0.63% | -54.0% | |
| RVP | Sell | RETRACTABLE TECHNOLOGIES INC | $594,951 | -22.6% | 499,959 | -25.2% | 0.55% | -21.1% |
| VRCA | VERRICA PHARMACEUTICALS INC | $582,750 | -32.7% | 150,000 | 0.0% | 0.54% | -31.3% | |
| New | VISTAGEN THERAPEUTICS INC | $524,000 | – | 100,000 | +100.0% | 0.48% | – | |
| LISATA THERAPEUTICS INC | $521,815 | -42.2% | 243,839 | 0.0% | 0.48% | -41.0% | ||
| QQQ | New | INVESCO QQQ TRput | $443,880 | – | 108 | +100.0% | 0.41% | – |
| NXTC | NEXTCURE INC | $395,340 | -28.3% | 306,465 | 0.0% | 0.36% | -26.8% | |
| New | NEOLEUKIN THERAPEUTICS INC | $389,723 | – | 98,664 | +100.0% | 0.36% | – | |
| CALCIMEDICA INC | $236,113 | -33.7% | 88,781 | 0.0% | 0.22% | -32.2% | ||
| RAIN | RAIN ONCOLOGY INC | $62,848 | -28.2% | 72,926 | 0.0% | 0.06% | -26.6% | |
| Sell | SURROZEN INC | $43,743 | -94.5% | 89,271 | -93.9% | 0.04% | -94.5% | |
| NLTX | Exit | NEOLEUKIN THERAPEUTICS INC | $0 | – | -23,749 | -100.0% | -0.02% | – |
| Exit | INVIVYD INC | $0 | – | -134,696 | -100.0% | -0.13% | – | |
| Exit | MEI PHARMA INC | $0 | – | -22,966 | -100.0% | -0.14% | – | |
| GRPH | Exit | GRAPHITE BIO INC | $0 | – | -152,291 | -100.0% | -0.36% | – |
| TLYS | Exit | TILLYS INCcl a | $0 | – | -190,518 | -100.0% | -1.20% | – |
| CRTX | Exit | QUINCE THERAPEUTICS INC | $0 | – | -1,411,839 | -100.0% | -1.91% | – |
| ANF | Exit | ABERCROMBIE & FITCH COcl a | $0 | – | -117,500 | -100.0% | -3.98% | – |
| Exit | PARDES BIOSCIENCES INC | $0 | – | -3,791,633 | -100.0% | -6.17% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-10-23
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SPDR SER TR | 4 | Q3 2023 | 16.9% |
| ADVERUM BIOTECHNOLOGIES INC | 4 | Q3 2023 | 7.4% |
| ELIEM THERAPEUTICS INC | 4 | Q3 2023 | 6.4% |
| ATHIRA PHARMA INC | 4 | Q3 2023 | 4.9% |
| ASTROTECH CORP | 4 | Q3 2023 | 2.8% |
| ARCA BIOPHARMA INC | 4 | Q3 2023 | 1.9% |
| FORTE BIOSCIENCES INC | 4 | Q3 2023 | 1.6% |
| VERRICA PHARMACEUTICALS INC | 4 | Q3 2023 | 2.9% |
| PASSAGE BIO INC | 4 | Q3 2023 | 1.7% |
| RETRACTABLE TECHNOLOGIES INC | 4 | Q3 2023 | 1.0% |
View BML Capital Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-04-24 |
| 13F-HR | 2024-04-23 |
| 13F-HR/A | 2024-02-02 |
| 13F-HR | 2024-01-30 |
| 13F-HR | 2023-10-23 |
| 13F-HR | 2023-07-24 |
| 13F-HR | 2023-04-14 |
| 13F-HR | 2023-02-13 |
View BML Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.